Sanofi offers hepatitis A vaccine for UK children

pharmafile | April 24, 2023 | News story | Medical Communications  

Sanofi has introduced a hepatitis A vaccine for children aged between one to 15 years old in the UK. The vaccine, inactive AVAXIM Junior, will consist of two doses injected intramuscularly six to 36 months apart. The doses can, however, be given up to seven years apart.


Hepatitis A is caused by the hepatitis A virus and is primarily transmitted through contaminated food and water, or by direct contact with an infected person. It is the most common form of viral hepatitis and the third most common vaccine-preventable infection among travellers.


The roll-out of AVAXIM Junior is supported by results from 20 clinical trials across 14 countries across Europe, the Middle East, Asia and the Americas. The trials included over 6,200 children from one to 15 years old, who have received at least one dose of AVAXIM Junior.


Results from the trials showed the vaccine is effective in triggering a protective antibody response within two weeks in more than 95% of individuals, and in 100% prior to the booster dose given six months after the first dose.


Sanofi Vaccines UK and Ireland general manager, Rebecca Catterick stated: “Hepatitis A is one of the most prevalent travel-related vaccine-preventable diseases, so the availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas.”


James Spargo

Related Content

No items found

Latest content